China
The Australian side, in particular, can benefit by capitalising on its independent status to bring in more work from Western countries while still working with its former Chinese partner
King & Wood Mallesons will break into two entities, 14 years after a merger between a Chinese and an Australian firm created the combined outfit
Xia Zheng, founder of AFD China, discusses balancing legal work with BD, new approaches to complex challenges, and the dangers of ‘over-optimism’
Stephen Yang joins us for our ‘Five minutes with’ series to explain why his role requires him to wear many hats
Recently published Special Focus articles
Recently published Special Focus articles
-
Sponsored by Wanhuida Intellectual PropertyXiaoping Wu of Wanhuida Intellectual Property explains how the CNIPA’s recent invalidation of a sustained-release patent illustrates key considerations in assessing inventive step for pharmaceutical formulation patents -
Sponsored by Liu, Shen & AssociatesWenjing Zhu of Liu, Shen & Associates explains how China’s administrative adjudication system is reshaping patent enforcement, offering faster, cost-effective, and technically expert resolutions for patentees, while preserving rights to pursue court remedies
-
Sponsored by Wanhuida Intellectual PropertyMinnan (Miranda) Xie of Wanhuida Intellectual Property analyses how China’s patent authorities and courts assess second medical use inventions, with key CNIPA decisions clarifying the treatment of dosage regimens and patient subgroups in novelty determinations
-
Sponsored by Liu, Shen & AssociatesHongbo Jia of Liu, Shen & Associates examines recent Supreme People’s Court cases that reshape Chinese patent litigation in addressing damages, patent validity, and pre-litigation injunctions, with important implications for multinational businesses
-
Sponsored by Wanhuida Intellectual PropertyAs an AstraZeneca patent survives a tenth invalidation challenge in China, Jianhui Li of Wanhuida Intellectual Property considers the implications for generic drug makers and the pharmaceutical industry
-
Sponsored by Liu, Shen & AssociatesRan Wang of Liu, Shen & Associates outlines the guidance the cited cases offer on issues such as patent evaluation reports, infringement judgments after invalidation, use environment features, and amendment rules
